军事知识服务平台
非小细胞肺癌围术期免疫治疗的模式演变:从辅助困境到新辅助优先
Evolution of Perioperative Immunotherapy Paradigms in Non-small Cell Lung Cancer:From Adjuvant Dilemma to Neoadjuvant Priority
摘要 免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)的应用重塑了可切除非小细胞肺癌(non-small cell lung cancer,NSCLC)的围术期治疗格局,目前已形成辅助、纯新辅助及"夹心饼"(新辅助+手术+辅助)三种治疗模式.尽管IMpower010和KEYNOTE-091在辅助免疫治疗中取得阳性结果,但BR.31和ANVIL两项大型III期研究的阴性结局,引发了对该模式的质疑.相比之下,新辅助免疫治疗在多项III期研究中均获得阳性结果,其机制可能在于保留了完整的肿瘤抗原库和引流淋巴结结构,使化疗联合ICIs能够诱导更强的免疫应答.目前纯新辅助和"夹心饼"模式均被指南推荐,但CheckMate-816与KEYNOTE-671的5年总生存(overall survival,OS)率几乎一致(65.4%vs 64.6%),且CheckMate-77T的病理完全缓解(pathological complete response,pCR)率(25.3%)与CheckMate-816(24%)亦相差无几,提示"夹心饼"模式中增加新辅助疗程和继续辅助免疫所带来的额外获益或许非常有限.未来,基于pCR和分子残留病灶(molecular residual disease,MRD)的个体化决策模型,如pCR且MRD阴性者降阶梯、non-pCR或MRD阳性者升阶梯,有望优化治疗强度与生存获益的平衡.综上,现有证据倾向可切除NSCLC采用"新辅助优先"策略:在疗效与"夹心饼"模式相当(上述比较主要基于跨研究间接比较)的前提下,纯新辅助模式更具成本效益优势,可作为首选;新辅助后的个体化治疗是未来的发展方向.
Abstract:
The application of immune checkpoint inhibitors(ICIs)has reshaped the perioperative treatment pattern of resectable non-small cell lung cancer(NSCLC).Currently,three treatment paradigms have emerged:adjuvant,neoadjuvant alone,and'sandwich'(neoadjuvant+surgery+adjuvant).Although IMpower010 and KEYNOTE-091 achieved positive results in adjuvant immunotherapy,the negative results of two large phase III studies,BR.31 and ANVIL,raised ques-tions about the generalizability of this model.In contrast,neoadjuvant immunotherapy has shown efficacy in multiple phase III studies.This advantage may stem from the preservation of the intact tumor antigen repertoire and draining lymph node architecture,enabling chemo-immunotherapy to elicit more robust systemic immune responses.Currently,both neoadjuvant alone and'sandwich'models are recommended by guidelines,but the 5-year overall survival(OS)rates of CheckMate-816 and KEYNOTE-671 are nearly identical(65.4%vs 64.6%),and the pathological complete response(pCR)rate of CheckMate-77T(25.3%)is comparable to that of CheckMate-816(24%),suggesting that the incremental benefit of extending neoadjuvant cycles and adding postoperative adjuvant immunotherapy in the'sandwich'model is very limited.In the future,an individual-ized decision-making model based on pCR and molecular residual disease(MRD)status,such as de-escalation to observation for those achieving pCR with negative MRD,and intensification for those with residual disease or positive MRD,is expected to optimize the balance between treatment intensity and survival benefit.In summary,the existing evidence favors the adoption of a'neoadjuvant first'strategy for resectable NSCLC.Based mainly on cross-trial indirect comparisons,the neoadjuvant alone model offers comparable efficacy to the'sandwich'approach with potential cost-effectiveness advantages,and may be preferred as the initial strategy.Individualized post-neoadjuvant management represents the future direction of this field.
刊 名 中国肺癌杂志 ISTICPKU
年,卷(期): 2026, 29(8)
机标分类号: R473.73 R734.2 TP302.8
在线出版日期: 2026年10月29日